Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia
Diabetologia - Clinical and Experimental Diabetes and Metabolism Dec 09, 2017
Hope SV, et al. - The clinicians aimed to ascertain whether random non-fasting C-peptide (rCP) measurement could be used to evaluate hypoglycaemia risk in insulin-treated type 2 diabetes. Among patients with insulin-treated type 2 diabetes, low rCP was correlated with increased glucose variability and hypoglycaemia. For assessment of hypoglycaemia risk, low rCP represented a practical, stable and inexpensive biomarker.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
